Angiogenesis-related protein expression in bevacizumab-treated metastatic colorectal cancer: NOTCH1 detrimental to overall survival

BACKGROUND: The development of targeted therapies has undoubtedly broadened therapeutic options for patients with colorectal cancer (CRC). The use of bevacizumab to reduce angiogenesis has been associated with improved clinical outcomes. However, an urgent need for prognostic/predictive biomarkers f...

Descripción completa

Detalles Bibliográficos
Autores principales: Paiva, Tadeu Ferreira, de Jesus, Victor Hugo Fonseca, Marques, Raul Amorim, da Costa, Alexandre André Balieiro Anastácio, de Macedo, Mariana Petaccia, Peresi, Patricia Maria, Damascena, Aline, Rossi, Benedito Mauro, Begnami, Maria Dirlei, de Lima, Vladmir Cláudio Cordeiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4579833/
https://www.ncbi.nlm.nih.gov/pubmed/26394830
http://dx.doi.org/10.1186/s12885-015-1648-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4579833/
https://www.ncbi.nlm.nih.gov/pubmed/26394830
http://dx.doi.org/10.1186/s12885-015-1648-4

Ejemplares similares